Highest-materiality recent filing
DaVita Q1 2026 adj EPS $2.87 vs $2.00 YoY; revenue $3.416B, repurchased 3M shares
GAAP and adjusted diluted EPS $2.87, up 44% YoY from $2.00; down sequentially from $3.40 in Q4 2025.
DaVita Q4 adj. EPS $3.40 vs $2.51 Q3; full-year net income down YoY
Q4 2025 revenue $3.620B, operating income $561M, adj. operating income $586M.
DaVita refinances $3.5B in credit facilities; JPMorgan replaces Wells Fargo as agent
Entered $2.0B secured term loan A facility (New A-2 Term Facility) and $1.5B secured revolving credit facility (New Revolving Facility).
DaVita Q3 2025 EPS $2.04, revenue $3.42B, in line with guidance
Diluted EPS of $2.04; adjusted diluted EPS of $2.51.
DaVita board authorizes additional $2 billion share repurchase program
Board authorized $2,000,000,000 in additional repurchasing authority under existing share repurchase program.
DaVita Q2 2025: EPS $2.58 ($2.95 adj.); revenue $3.38B; $1B notes issued
Diluted EPS $2.58 ($2.95 adjusted); net income $199M vs Q1 $163M.
DaVita reprices $1.88B term loan B, cuts margin 25 bps, adds $250M incremental debt
Seventh Amendment to Credit Agreement reprices $1.628B Extended Tranche B-1 Term Loans into Tranche B-2 at 175 bps (Term SOFR) and 75 bps (Base Rate), down from 200/100 bps.
DaVita stockholders elect all nine directors, ratify KPMG, approve say-on-pay at 2025 annual meeting
All nine director nominees elected with >97% votes cast in favor; broker non-votes ~6.4M shares.
DaVita closes $1.0B offering of 6.750% Senior Notes due 2033
Issued $1.0B aggregate principal of 6.750% senior notes maturing July 15, 2033.
DaVita announces private offering of $750M Senior Notes due 2033
$750M aggregate principal amount of 2033 Senior Notes offered in private placement.
DaVita upsizes and prices $1B of 6.750% Senior Notes due 2033
Offering increased from $750M to $1B aggregate principal; notes priced at 100.000% with 6.750% coupon.
DaVita Q1 2025: revenue $3.22B, EPS $2.00, net income $163M down 32% YoY
Consolidated revenues $3.224B; operating income $439M.
DaVita reports ransomware incident on April 12; operations impacted, patient care continues
Ransomware encrypted certain network elements; DaVita isolated impacted systems and activated response protocols.
DaVita Q4 adjusted EPS $2.24, revenue $3.295B; full year EPS $10.73
Q4 2024 revenue $3.295B; operating income $565M; diluted EPS $3.09 (adjusted $2.24).
DaVita Q3 2024: revenue $3.264B, op income $535M, EPS $2.50, adj EPS $2.59
Consolidated revenue $3.264B; operating income $535M; net income $215M ($2.50 diluted EPS).
DaVita appoints David P. Maughan as COO, Kidney Care; Staffieri becomes COO Emeritus
David P. Maughan appointed COO, DaVita Kidney Care, effective September 15, 2024, succeeding Michael D. Staffieri.
DaVita board approves $2B increase to share repurchase program
Board added $2B in repurchase authority; no expiration date, no obligation to repurchase.
DaVita issues $1.0B of 6.875% senior notes due 2032 and obtains $1.1B term loan facility
Issued $1.0B aggregate principal of 6.875% Senior Notes due September 1, 2032.
DaVita prices $1.0B of 6.875% Senior Notes due 2032; proceeds for debt repayment
$1.0B aggregate principal, 6.875% coupon, priced at par, due 2032; closing August 13, 2024.
DaVita launches $1.0B senior notes due 2032; proceeds to repay Term Loan B-1 and revolver
$1.0B aggregate principal of Senior Notes due 2032 in a private offering under Rule 144A/Reg S.
DaVita Q2 2024 EPS $2.50, revenue $3.187B; raises adjusted EPS to $2.59
Net income $223M, diluted EPS $2.50; adjusted EPS $2.59 on revenue of $3.187B.
DaVita holds 2024 annual meeting; all director nominees elected, KPMG ratified, say-on-pay approved
Ten director nominees elected with majority support; broker non-votes of ~6.96M.
DaVita extends $1.64B term loan maturity to 2031, adds $658M incremental term loans
Extended $1,640,250,847 of existing secured term loans from August 2026 to May 2031.
DaVita Q1 2024 net income $240M, EPS $2.65; revenue $3.07B
Revenue $3.071B; operating income $484M; adjusted operating income $463M.
David P. Maughan, Senior Vice President of the Company, has been appointed Chief Operating Officer, DaVita Kidney Care, effective September 15, 2024
Mr. Maughan will replace Michael D. Staffieri, who will transition to the role of Chief Operating Officer Emeritus, as of the Effective Date.
Max materiality 0.80 · Median 0.65 · Most common event earnings